SAFE-BioPharma® Approves Exostar as Full Service Credential Service Provider
TENAFLY, N.J.--(BUSINESS WIRE)--Exostar, whose cloud-based solutions enable secure, cost-effective information sharing and collaboration among pharmaceutical, healthcare, and other industries, has been approved as a Full Service Credential Service Provider (CSP) by the SAFE-BioPharma Trust Framework.
“As a SAFE-BioPharma CSP, our non-PKI LOA-3 credentials are certified to align with Federal Identity, Credential, and Access Management (FICAM) requirements. That trust will encourage more organizations to connect to our Life Sciences Identity Hub and fully leverage our credentials to collaborate with confidence across the community.”
As a CSP, Exostar can now issue National Institute of Standards and Technology Level of Assurance 3 (LOA-3) non-public key infrastructure (PKI) electronic identity credentials compliant with the global SAFE-BioPharma digital identity and digital signature standard. LOA-3 credentials can be used to authenticate cyber identities to most online services in regulated industries such as pharmaceuticals and healthcare.
"Exostar's new status under the SAFE-BioPharma Trust Framework allows it to further enhance secure and trusted collaboration in the biopharmaceutical and healthcare sectors. This is important for Exostar and for the industry," said Mollie Shields Uehling, president and CEO, SAFE-BioPharma Association.
Exostar's federated identity hubs allow participating organizations such as business partners, external researchers, and government agencies to quickly and cost-effectively provide secure and trusted access to one another’s proprietary toolsets, analytics, and other cloud-based or on-premises internal/external applications. The company maintains separate identity hubs for the Life Sciences and the aerospace and defense industries.
Its Life Sciences Identity Hub currently brings together over 500 organizations and 10,000 individuals worldwide. It controls access to applications, sensitive data, and intellectual property by authenticating identity credentials including Exostar-issued one-time password tokens compliant with the global SAFE-BioPharma digital identity standard.
“We are building a community that lets life sciences and healthcare organizations collaborate securely and productively, and that empowers them to bring life-saving new drugs to market faster and improve patient care,” said Daniel Pfeifle, Exostar’s Vice President of Sales and Marketing. “As a SAFE-BioPharma CSP, our non-PKI LOA-3 credentials are certified to align with Federal Identity, Credential, and Access Management (FICAM) requirements. That trust will encourage more organizations to connect to our Life Sciences Identity Hub and fully leverage our credentials to collaborate with confidence across the community.”
The global SAFE-BioPharma digital identity and digital signature standard is used throughout the biopharmaceutical and healthcare communities to meet specific security and confidentiality needs. For more information visit http://www.safe-biopharma.org.
SAFE-BioPharma® is a trademark of SAFE-BioPharma Association. Any use of this trademark requires approval from SAFE-BioPharma Association.
Exostar powers secure business-to-business information sharing, collaboration and business process integration throughout the value chain. Exostar supports the complex trading needs of many of the world's largest companies in aerospace and defense, life sciences, and other industries. Exostar’s cloud-based identity assurance products and business applications reduce risk, improve agility and strengthen trading partner relationships and profitability for over 100,000 companies in 150 countries worldwide. The Exostar community includes market leaders such as AstraZeneca, BAE Systems, Bell Helicopter, The Boeing Company, Computer Sciences Corporation, Lockheed Martin Corp., Merck, Newport News Shipbuilding, Northrop Grumman, Raytheon Co. and Rolls-Royce. For more information, please visit www.exostar.com.